Behavioral study on the novel anti-dementia drug repurposed as treatment for the Alzheimer's disease
Description: In the present study, we revealed that the PDE3 inhibitor cilostazol improved the impaired learning and memory function in a mouse model of Alzheimer’s disease. This results suggest that cilostazol might be a possible therapeutic intervention for the treatment of Alzheimer’s disease. In addition, sub-effective doses of cilostazol and donepezil in combination recovered memory function. These results suggest that the combination therapy comprising two or more drugs may offer a new pharmacological approach for treating cognitive disorders, as the combination therapy demonstrated to be an effective strategy for treating some types of diseases.
Amount: ¥4,420,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2018-04-01
End date: 2021-03-31
Investigator: Shuichi Yanai
Institution: Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 7
Funder award ID: 18K07460
OpenAlex ID: G6327472153